Download Unicorn Signals App

By EquityPandit

BUSINESSLatest News

Hindalco Zooms on Completion of Aleris Acquisition

The shares of Hindalco Industries gained as much as 9 per cent on Wednesday after the company completed the acquisition of US-based Aleris Corporation through its wholly-owned subsidiary Novelis Inc.
At 12:55 pm, the shares were trading at Rs 119.85, up 4.32 per cent from its previous close, while the benchmark index Sensex gained 1.77 per cent and the BSE Metals index gained 3.75 per cent.
The acquisition of the US-based rolled products major, Aleris Corporation, positions Hindalco as one of the world’s largest aluminium companies, with a global footprint spanning 49 manufacturing facilities in North America, Europe and Asia.
With the addition of Aleris’ operational assets and workforce, Novelis is poised to serve the growing Asia market by integrating complementary assets in the region, including recycling, casting, rolling and finishing capabilities.On a trailing 12-month basis ended 31 December, legacy standalone Aleris’ adjusted EBITDA stood at $388 million, higher than that estimated at the time of deal announcement. Novelis will acquire Aleris’ 13 plants across North America, Europe and Asia. However, to satisfy regulatory conditions, the company is required to divest Aleris’ plants in Lewisport, Kentucky, US, and Duffel, Belgium, as announced earlier.
Read EquityPandit’s Nifty Outlook for the Week

Get Daily Prediction & Stocks Tips On Your Mobile


I would like to receive communication from EquityPandit via sms, email, whatsapp, Google RCS for offers, updates etc.
MARKETS

Lupin Secures USFDA Approval for Tolvaptan Tablets; Shares Gain 

Ali Waghbakriwala

Shares of Lupin Ltd were trading in the green and 2% higher on Thursday, 24 April, after the company announced that USFDA (US Food and Drug Administration) had approved its Abbreviated New Drug Application (ANDA) for Tolvaptan tablets, which are intended to delay the deterioration of kidney function.

In an exchange filing, the company stated that it was the first to file for the product, providing it with 180 days of generic exclusivity. The medication is currently being produced at Lupin’s Nagpur facility and will be available shortly.

Tolvaptan delays the decline of kidney function in people suffering from rapidly progressive autosomal dominant polycystic kidney disease (ADPKD). According to Lupin’s exchange report, tablet sales in the United States will be over $1.47 billion by 2024.

“We are very pleased to have obtained approval for generic Tolvaptan from the USFDA. This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally,” said Lupin CEO Vinita Gupta.

Otsuka Pharmaceutical developed Tolvaptan tablets, a bioequivalent of Jynarque, to treat autosomal dominant polycystic kidney disease (ADPKD), a chronic condition with few therapies.

At 2:39 pm, the shares of Lupin Ltd were trading 0.69% higher at Rs 2,104 on NSE. 

Ask the analyst & get instant answer about Lupin Ltd.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!

MARKETS

Persistent Systems Shares Rally 4% on Strong Q4 Earnings 

Ali Waghbakriwala

Shares of Persistent Systems Ltd rallied 4% on 24 April after the company announced its quarterly earnings for the fourth quarter of the fiscal year 2025.

Persistent Systems reported a total net profit of Rs 395.76 crore for the period under review, reflecting a 25.5% year-on-year (YoY) rise over the net profit of Rs 315.32 crore achieved in Q4 FY24. In Q4 FY25, the company’s operating revenue rose by more than 25% year on year to Rs 3,242 crore.

For the fiscal year ending 31 March 2025, the IT company announced a final dividend of Rs 15 per equity share in addition to its Q4 results. According to an exchange filing, the record date for determining whether stockholders are eligible to receive the payout will be made public later. The dividend given this year now stands at Rs 35, which is noteworthy. According to the firm, it planned to commemorate its 35th anniversary.

Persistent CEO and Executive Director Sandeep Kalra said, “We are proud to have delivered our 20th sequential quarter of revenue growth, with an EBIT margin of 15.6%…Despite the uncertain macroeconomic environment, our consistent performance reflects the trust of our clients, enduring strength of our capabilities, and operational discipline.”

Sandeep added, “As we look ahead, we are optimistic about sustaining progress to reach $2 billion in annual revenue by FY27. Our strategic pivot to AI-led platform-driven services will drive this growth, fueled by continued rigor and innovation. We are well-positioned to continue delivering consistent and differentiated long-term value for all our stakeholders.”

For the fourth quarter of fiscal year 25, the firm reported a Total Contract Value (TCV) of $517.5 million and an Annual Contract Value (ACV) of $350.2 million.

Persistent Founder, Chairman and Managing Director Anand Deshpande said, “Persistent is leading the AI-led transformation, supported by early investments, strong execution, and a clear vision to embed AI across our clients’ digital journey. Celebrating 35 years since our foundation and 15 years of being publicly listed on the National Stock Exchange of India, our unwavering commitment to innovation and client success continues to set us apart as we drive the future of technology with purpose and precision.”

At 2:02 pm, the shares of Persistent Systems were trading 0.56% higher at Rs 5,192.50 on NSE.

Stay Ahead with Persistent Systems Ltd. Ask the Analyst.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!

MARKETS

Thyrocare Shares Skyrocket 18% on Stellar Q4 Earnings 

Ali Waghbakriwala

Shares of Thyrocare Technologies Ltd Skyrocketed 18% on Thursday, 24 April, after the company reported strong financial results for the January-March quarter (Q4FY25).

The company’s net profit for the quarter ending March 2025 climbed by 21.9% year on year (YoY) to Rs 21.7 crore from Rs 17.8 crore in the same period last year. Profit growth was driven mostly by improved operational performance and a consistent increase in the number of diagnostic tests performed.

The revenue for the quarter increased by 21.3% YoY, from Rs 154.3 crore in Q4FY24 to Rs 187.2 crore. EBITDA, or earnings before interest, taxes, depreciation, and amortisation, increased by 70.5% to Rs 57.8 crore.

As a result, the EBITDA margin jumped to 30.9% from 22% during the same time last year. This signifies enhanced operational efficiency and cost control.

The company’s board has recommended a final dividend of Rs 21 per equity share for FY25; shareholder approval is currently pending.

Thyrocare, headquartered in Navi Mumbai, operates a vast network of diagnostic and preventative healthcare laboratories throughout India. In recent quarters, the company has concentrated on increasing its test offerings and strengthening its digital presence, which has contributed to revenue growth driven by increased testing volumes.

At 12:24 pm, the shares of Thyrocare Tech were trading 13.44% higher at Rs 872.60 on NSE. 

Wondering About Thyrocare Technologies Ltd? The Analyst Has Answers.

The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!

MARKETS

Samhi Hotels Shares Soar 10% on Strategic Partnership with GIC 

Ali Waghbakriwala

Shares of Samhi Hotels Ltd soared 10% on 24 April after the company announced a strategic partnership with global institutional investor GIC. 

As part of the agreement, GIC would buy a 35% ownership in Samhi’s subsidiaries, which include the upscale hotels Hyatt Regency in Pune, Courtyard & Fairfield by Marriott in Bengaluru ORR, and the recently acquired Trinity Hotel in Bengaluru Whitefield.  

The aforementioned transaction, with an enterprise value of Rs 2,200 crore, would require an investment of around Rs 752 crore, from which Rs 603 crore of the amount would be used to pay off Samhi’s debt and cover transaction expenses. The remaining funds will be used to partially fund capital expenditures for the dual-branded Westin or Tribute Portfolio Bengaluru Whitefield hotel over the next two years.

Following the transaction, the company intends to reduce its debt by approximately Rs 580 crore. Samhi estimated that this would raise the company’s net profit by 15%-20%.  Furthermore, its net debt-to-EBITDA ratio is forecast to reduce from 4.9x to 3.5x following the deal and subsequently to 3x during the following year.

The company, in its regulatory filing, added, “The transaction follows our stated strategy of capital recycling and will lead to significant reduction in debt and partnership with a global investor of GIC’s stature for funding further growth.”

The company added that the debt reduction and partial finance of new projects will significantly increase its future cashflows.

At 11:42 am, the shares of Samhi Hotels were trading 9.22% higher at Rs 190 on NSE. 

Curious About Samhi Hotels Ltd? Ask the Analyst.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!

MARKETS

Stocks in Focus: Bharat Petroleum, Adani Green Energy, Panacea Biotec, and Others

Ali Waghbakriwala

The GIFT Nifty futures, which is an early indicator of the Nifty50 index, was trading 0.25% lower by 61 points at 24,251, indicating that the domestic benchmark indices are likely to make a negative start on Thursday.

On Wednesday, 23 April, Domestic benchmark indices S&P BSE Sensex gained by 520.9 points or 0.65% and settled at 80,116.4 while the Nifty50 traded 0.67% higher by 161.7 points, settling at 24,328.

Here are some stocks that are likely to remain in focus on 24 April.

Quarterly Results Today: SBI Life Insurance Company, Tech Mahindra, Hindustan Unilever, Axis Bank, Nestle India, ACC, Indian Energy Exchange, Laurus Labs, Adani Energy Solutions, Cyient, Macrotech Developers, L&T Technology Services, Persistent Systems, SBI Cards and Payment Services, Mphasis, Nelco, Supreme Industries, Sterling and Wilson Renewable Energy, Waaree Technologies, and Tanla Platforms are some of the prominent companies set to announce their quarterly earnings for January-March. 

Bharat Petroleum: The company has announced its intention to enter into a joint venture agreement with GPS Renewables Pvt ltd to set up compressed biogas plants across India. Through this joint venture, the company aims to deploy advanced waste-to-energy technologies to convert organic biomass waste into compressed biogas. 

Adani Green Energy: The subsidiary of the company, Adani Hydro Energy Five, has announced the signing of a power purchase agreement with Uttar Pradesh Power Corporation to supply 1,250 MW of energy storage capacity from pumped hydro storage projects.

Panacea Biotec: The company has announced that it is securing an additional order worth Rs 44 crore ($5.2 million) to supply 40 million doses of its bivalent oral polio vaccine from UNICEF. 

Bajaj Housing Finance: In its quarterly earnings for January-March, the company reported a 54% year-on-year (YoY) increase in net profit to Rs 587 crore for the quarter under review compared to Rs 381 crore reported in the same quarter last year. 

Tata Consumer Products: For the quarter ended 31 March, the company reported a net profit of Rs 344.85 crore, marking a 59.19% YoY increase against Rs 216.63 crore reported in the same quarter last year. 

NHPC: The company announced that it will develop a 1,200 megawatt (MW) solar park in Uttar Pradesh under the MNRE Scheme for a total cost of Rs 797 crore that includes the investment of Rs 239 crore in Bundelkhand Saur Urja, which is a subsidiary of the company. 

Embassy Office Parks REIT: The Board of Directors of the company has approved raising funds in tune with Rs 6,500 crore through the issuance of commercial papers worth Rs 675 crore and debt, which will be used to repay its existing debt and working capital needs.

Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!

Latest
IPO
Weekly
Outlook

Stock
Market
Prediction